VICTORIA, BC, Dec. 23, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSXV: IPA) (Nasdaq Global Markets:
IPA), a leader in full-service, therapeutic antibody discovery and
development, is pleased to announce that its common shares have
been approved for listing on the NASDAQ Global Market
("Nasdaq") under the trading ticker symbol
"IPA." Trading on the Nasdaq is expected to commence at
market open on December 30, 2020.
The Company's Shares will continue to be listed on the TSX
Venture Exchange ("TSX-V") under the symbol
"IPA".
"Our listing on the NASDAQ is a major corporate milestone and
reflects the hard work and steadfast dedication of IPA's global
employees and executive team," stated Dr. Jennifer Bath, CEO of IPA. "We believe the
NASDAQ Global Market will enhance long-term shareholder value by
improving the Company's visibility, increasing liquidity, and
appealing to institutional investors."
About ImmunoPrecise Antibodies Ltd.
IPA is a global
technology platform company with end-to-end solutions empowering
companies to discover and develop therapies against any disease.
The Company's experience and cutting-edge technologies enable
unparalleled support of its partners in their quest to bring
innovative treatments to the clinic. IPA's full-service
capabilities dramatically reduce the time required for, and the
inherent risk associated with, conventional multi-vendor product
development. For further information, visit
www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
Certain statements included in this release may be
"forward-looking statements" within the meaning of Canadian
securities laws, including statements regarding the listing of the
Company's Shares on Nasdaq and the timing of commencement of the
Shares on Nasdaq.
Forward-looking statements are typically identified by the
use of terminology such as "may", "will", "would", "could",
"expects", "plans", "intends", "anticipates" or "believes" or the
negative or other variations of these words or other comparable
words or phrases. Forward-looking statements, by their nature, are
based on assumptions, and are subject to important risks and
uncertainties. Forward-looking statements cannot be relied
upon due to, amongst other things, changing external events and
general uncertainties of the business. Completion of the
proposed listing on Nasdaq is subject to numerous factors, many of
which are beyond IPA's control, including important factors
disclosed previously and from time to time in IPA's filings with
the securities regulatory authorities in each of the provinces of
Canada and the U.S. Securities and
Exchange Commission. The forward-looking statements contained in
this release represent IPA's expectations as of the date of this
release (or as of the date they are otherwise stated to be made),
and are subject to change after such date. However, IPA
disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information,
future events or otherwise, except as required under applicable
securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.
